Study on Gene Evolution in Glioma Under Stress Therapy
ConditionGenetic Change
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorHenan Provincial People's Hospital
About this trial
Little is known about the evolution of genetic and epigenetic changes that occur in the progression of glioma. We inferred the evolution trajectories of matched pairs of primary tumors and progression tumor in situ fluid (TISF) based on deep whole-genome-sequencing data (ctDNA). A monocentric, Gene grouping controlled trial design was used to select patients. and to compare gene evolution of different subtypes of glioma under therapy. To predict the molecular reaction of bevacizumab treatment, clarify the mechanism of drug resistance of bevacizumab treatment.
Eligibility criteria
Qualifiers
Age 18 to 75 years, both male and female (including 18 and 75 years old) glioma;
Willing to accept treatment and sign informed consent.
Disqualifiers
Participants with other infection disease or immunodeficiency disease;
other central infectious diseases;
malignant tumor of non-nervous system;
drug abuse;
Trial design
Treatments tested in this trial
- Gene evolution and molecular response under Bevacizumab treatment
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov